Suppr超能文献

低收入男性转移性前列腺癌手术后生活质量。

Quality of life in low-income men after surgical castration for metastatic prostate cancer.

机构信息

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA.

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA.

出版信息

Urol Oncol. 2022 Jul;40(7):343.e7-343.e14. doi: 10.1016/j.urolonc.2022.04.009. Epub 2022 May 15.

Abstract

OBJECTIVE

To compare health-related quality of life in men who underwent surgical vs. medical castration for metastatic prostate cancer.

METHODS

We analyzed data from a prospective cohort of men enrolled in a statewide public health program that provides care for prostate cancer among low-income, uninsured men from 2001 to 2020. Outcome measures included the RAND SF-12 and the UCLA Prostate Cancer Index (PCI) at baseline and every 6 months. We used generalized estimating equations to assess the independent impact of surgical vs. medical castration on health-related quality of life.

RESULTS

Among men with metastatic prostate cancer, 27 underwent orchiectomy, and 274 underwent medical castration. Median cohort age at enrollment was 61.3 years (IQR 56-65); 239 (79%) men had less than a high school education. Average follow-up was 8 months (range 0-45) since study enrollment. Seventy percent of patients within the surgical castration group had their orchiectomy prior to study enrollment (median months since orchiectomy at study enrollment was 9 months, IQR 1-43). Similarly, 59% of patients within the medical castration group had begun ADT prior to study enrollment (median months since ADT initiation at study enrollment was 4 months, IQR 1-12). The majority (66%) had metastatic disease at diagnosis. The 2 groups did not differ in age, race/ethnicity, education, monthly income, baseline PSA, Gleason score, or percent metastatic at diagnosis. SF-12 domains did not differ between those who underwent surgical vs. medical castration (on average throughout follow-up, physical component difference -2.0, 95% CI -8.0-3.9 and mental component difference -1.0, 95% CI -5.4-+3.4). Patients treated with orchiectomy reported better urinary function than those who underwent medical castration (+16 point, 95%CI 5.3-26).

CONCLUSIONS

Surgical castration did not negatively impact general or disease-specific quality of life. The finding of improved urination after orchiectomy merits further inquiry. This may inform urologists' discussion of surgical vs. medical options for men with castration-sensitive metastatic prostate cancer.

摘要

目的

比较接受手术去势与药物去势治疗转移性前列腺癌的男性的健康相关生活质量。

方法

我们分析了 2001 年至 2020 年期间,参与一个为低收入、无保险的男性提供前列腺癌护理的全州公共卫生项目的前瞻性队列中的男性数据。结局指标包括基线和每 6 个月的 RAND SF-12 和 UCLA 前列腺癌指数(PCI)。我们使用广义估计方程评估手术去势与药物去势对健康相关生活质量的独立影响。

结果

在转移性前列腺癌男性中,27 例接受了睾丸切除术,274 例接受了药物去势。队列中位入组年龄为 61.3 岁(IQR 56-65);239 例(79%)男性受教育程度低于高中。自研究入组以来,平均随访时间为 8 个月(范围 0-45)。手术去势组中 70%的患者在研究入组前已行睾丸切除术(研究入组时距睾丸切除术的中位时间为 9 个月,IQR 1-43)。同样,药物去势组中 59%的患者在研究入组前已开始 ADT(研究入组时距 ADT 开始的中位时间为 4 个月,IQR 1-12)。大多数(66%)患者在诊断时已发生转移。两组在年龄、种族/民族、教育程度、月收入、基线 PSA、Gleason 评分或诊断时转移百分比方面无差异。SF-12 各领域在接受手术去势与药物去势的患者之间无差异(平均随访期间,身体成分差异-2.0,95%CI-8.0-3.9,心理成分差异-1.0,95%CI-5.4-+3.4)。接受睾丸切除术的患者报告的尿功能优于接受药物去势的患者(+16 分,95%CI 5.3-26)。

结论

手术去势不会对总体或疾病特异性生活质量产生负面影响。睾丸切除术改善排尿的发现值得进一步研究。这可能为泌尿科医生讨论对去势敏感的转移性前列腺癌患者的手术与药物治疗选择提供信息。

相似文献

本文引用的文献

5
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.晚期前列腺癌:AUA/ASTRO/SUO 指南 PART I.
J Urol. 2021 Jan;205(1):14-21. doi: 10.1097/JU.0000000000001375. Epub 2020 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验